ArticleTherapeutic advances in ophthalmology
Intralesional rituximab injections for orbital granulomatosis with polyangiitis: a case series and literature review.
Article in Therapeutic advances in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab, an anti-CD-20 monoclonal antibody, has garnered increasing interest as a therapeutic option in orbital inflammatory disease (OID). We report our institutional experience with intralesional rituximab injections in two cases of orbital granulomatosis with polyangiitis (GPA), and additionally review the literature surrounding intralesional rituximab in OID. Two patients (a 74-year-old male (Case 1) and a 63-year-old female (Case 2)) with orbital GPA received intralesional rituximab injections at our tertiary institution. Case 1 had evidence of left optic neuropathy in extensive bilateral inferomedial orbital inflammation, while Case 2 had severe refractory and relapsing left orbital inflammation. Both patients received intralesional rituximab injections (Riximyo 10 mg/ml), administered weekly over 8-11 weeks. Rituximab injections were adjunctive to systemic induction therapy, including corticosteroids and rituximab infusion in Case 1, and a course of corticosteroids only in Case 2. Both patients demonstrated a clinico-radiological response to treatment. In conclusion, we present our experience with intralesional rituximab injections, used as an adjunctive treatment modality for orbital GPA, in a case of optic neuropathy and another of severe, refractory, and relapsing disease. Further prospective studies are required to define its utility and the long-term outcomes of intralesional rituximab injections in OID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.